UPAR Ultra Risk Parity ETF UPAR
15.14 USD -0.15 (-0.97%)
At closeNov 3, 2026, 7:30 PM EST
15.14 0.00 0.00%
After hours · Nov 3, 7:30 PM ET
15.11 Day range 15.25
14.77 52-week range 17.71
- YTD
- -2.05%
- 1 year
- -1.67%
- Market cap
- 55.30M
- EPS (ttm)
- 0.825617
- P/E ratio
- 18.34
- YTD return
- -2.05%
- 1-year return
- -1.67%
- Volume
- 3.51K
- Avg volume
- 6.66K
- Open
- 15.25
- Previous close
- 15.29
- Day's range
- 15.11 – 15.25
- 52-week range
- 14.77 – 17.71
2Y +1.13 (+8.05%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 13.94
- 200-day average
- 13.89
About UPAR Ultra Risk Parity ETF
The fund is an actively-managed ETF that seeks to replicate the returns of the Advanced Research Ultra Risk Parity Index (the “UPAR Index”). The UPAR Index is designed to provide leveraged exposure to the RPAR Index by using an implied financing rate to target 1.4 times the asset class exposures of the RPAR Index at each quarterly rebalance. It is non-diversified.
News
Hedge Funds Swap Yen For Dollar In New Carry Trade Strategy: Report 
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones 
Conjugated Monoclonal Antibodies Global Market Research Report 2022 - ResearchAndMarkets.com 
Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com 
Toroso Launches Leveraged ETF for Investors Seeking More Upside 
Real-Time Monitoring of Melanoma Cell Invasion Helps Scientists
Elucidate Key Regulators of Metastasis 
Onxeo concède à Monopar Therapeutics une licence mondiale
exclusive de Validive®, développé dans le traitement de la mucite orale
sévère 
Onxeo Grants Exclusive Worldwide License of Validive® Developed
for the Treatment of Oral Severe Mucositis to Monopar Therapeutics
Your note
Sign in to keep a note on UPAR — it syncs with the Stock Master app.